

International Application No. .
PCT/Ge 03/00811

IPC 7	A61K39/00	A61K39/02	A61K39/12	C07K16/28	C07K14/705
	C12N15/12	C12N15/33	C12N15/31	C12N15/62	C12N15/63

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

BIOSIS, MEDLINE, EPO-Internal, WPI Data, PAJ, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SEINO KEN-ICHIRO ET AL: "Antitumor effect of locally produced CD95 ligand." NATURE MEDICINE, vol. 3, no. 2, 1997, pages 165-170, XP002076955 ISSN: 1078-8956 cited in the application abstract page 165, right-hand column page 166, left-hand column, paragraph 1 page 167, left-hand column, paragraph 3 page 167, right-hand column, paragraph 1 - paragraph 2 page 168, left-hand column, paragraph 1 - paragraph 3</p>	<p>1-3,6,7, 12,13, 15-19</p>
Y	<p>---</p> <p>-/--</p>	<p>8-10</p>

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another claim or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *¹ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *² document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *³ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *⁴ document member of the same patent family

Date of the actual completion of the International search

14 October 2003

Date of mailing of the international search report

03/11/2003

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Iron, A

Best Available Copy

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/GB 03/00811

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WALKER PAUL R ET AL: "Tumor expression of Fas ligand (CD95L) and the consequences." CURRENT OPINION IN IMMUNOLOGY, vol. 10, no. 5, October 1998 (1998-10), pages 564-572, XP004327282 ISSN: 0952-7915 page 564, left-hand column page 566, left-hand column page 565, left-hand column	1-3,6,7, 12,13, 15-19
X	SHIMIZU M ET AL: "Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells." JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 15 JUN 1999, vol. 162, no. 12, 15 June 1999 (1999-06-15), pages 7350-7357, XP002255930 ISSN: 0022-1767 abstract	1-3,6,7, 12,13, 15-19
X	WO 98 26061 A (UNIV CALIFORNIA) 18 June 1998 (1998-06-18) page 53, line 19 - line 25 claims 11,20,50,55 page 7, line 16 - line 30 page 8, line 17 - line 18 page 54, line 3 - line 8 page 53, line 32 - line 34	1-4,6,7, 12,13, 15-19
P,X	TADA YUJI ET AL: "T cell dependent and independent antitumor immunity generated by the expression of Fas ligand on mouse lung carcinoma cells." INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol. 9, no. 3, March 2002 (2002-03), pages 281-285, XP009017374 ISSN: 1107-3756 the whole document	1-3,6,7, 12,13, 15-19
Y	ONIZUKA SHOZABURO ET AL: "Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody." CANCER RESEARCH, vol. 59, no. 13, 1 July 1999 (1999-07-01), pages 3128-3133, XP002255931 ISSN: 0008-5472 the whole document	8-10

-/--

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/GB 03/00811

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>SIMON ANNA KATHARINA ET AL: "Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies." CANCER CELL, vol. 2, no. 4, October 2002 (2002-10), pages 315-322, XP002255932 October, 2002 ISSN: 1535-6108 the whole document</p>	1-27

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

Best Available Copy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/GB 03/00811

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9826061	A	18-06-1998	AU 5795798 A	03-07-1998
			BR 9714004 A	02-05-2000
			CN 1246892 A	08-03-2000
			EP 0948614 A2	13-10-1999
			JP 2001505782 T	08-05-2001
			NO 992756 A	09-08-1999
			NZ 336092 A	28-09-2001
			WO 9826061 A2	18-06-1998